Nuclivision is a Ghent-based medtech founded in 2022 that develops Nuclarity, an AI software platform to enhance PET imaging. Nuclarity aims to shorten scan times and lower required radiotracer doses while preserving image quality. The company targets PET use cases in cancer and Alzheimer’s diagnosis and treatment planning. Nuclivision is in the final phase of regulatory approval and plans a European commercial launch with a U.S. entry expected later this year. The business recently secured external funding to support the commercial rollout of its flagship product. The company is presented as part of a broader wave of European deeptech startups applying AI to complex healthcare procedures. Nuclivision offers an AI-driven imaging platform that automates the identification of symptoms on PET readouts, enabling faster diagnoses without undermining accuracy. The company targets nuclear medicine workflows to reduce costs and lower radioactive exposure for patients and staff. It was founded last June by Gregor Strobbe, Nikos Paragios, Jean-Briac Prévost, Alex Maes, Roland Hustinx, Stefaan Vandenberghe and Dr. Sezgin Üstmert. Nuclivision is based in Ghent. The startup disclosed a fundraising from Ghent VC Luminaires and says it expects to have sufficient runway to refine its PET product. The articles highlight the company’s mission to make nuclear imaging and therapies more accessible and more cost-effective.

Total raised

$6M

Funding rounds

2

Latest round

Seed

Latest activity

Apr 2025